General Information of Drug (ID: DMMBJYC)

Drug Name
ZYH-1 Drug Info
Synonyms Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila
Indication
Disease Entry ICD 11 Status REF
Lipid metabolism disorder 5C52.Z Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMMBJYC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [3]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [4]
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [5]
Rosiglitazone XR DMT45MU Type-2 diabetes 5A11 Approved [6]
Thiazolidinedione DMC1NBW Alzheimer disease 8A20 Approved [4]
Glitazone DMDN4A1 N. A. N. A. Phase 4 [7]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [8]
Rivoglitazone DMBY31K Ocular inflammation 9C61.24 Phase 3 [9]
Balaglitazone DMXBHR6 Type-1 diabetes 5A10 Phase 3 [10]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [5]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [7]
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [12]
Ciprofibrate DMGC5DB Hyperlipoproteinemia 5C80 Approved [7]
Pemafibrate DMD1VZL Hyperlipidemia 5C80.Z Approved [13]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [8]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [11]
CS-038 DM67P0F Type-2 diabetes 5A11 Phase 3 [14]
TESAGLITAZAR DMGRBN5 Type-1 diabetes 5A10 Phase 3 [15]
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Modulator [2]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) TTZMAO3 PPARG_HUMAN Modulator [2]

References

1 A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 g compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014 Feb;16(2):63-71.
2 Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
3 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
4 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
5 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
8 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
9 A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
10 Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
11 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
12 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
13 Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
14 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
15 Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
16 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.